Phan V, Blydt-Hansen T, Feber J, Alos N, Arora S, Atkinson S, Bell L, Clarson C, Couch R, Cummings E A, Filler G, Grant R M, Grimmer J, Hebert D, Lentle B, Ma J, Matzinger M, Midgley J, Pinsk M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Williams K, Rauch F, Siminoski K, Ward L M
Université de Montréal, Montréal, QC, Canada.
Osteoporos Int. 2014 Feb;25(2):627-37. doi: 10.1007/s00198-013-2466-7. Epub 2013 Aug 16.
Incident vertebral fractures and lumbar spine bone mineral density (BMD) were assessed in the 12 months following glucocorticoid initiation in 65 children with nephrotic syndrome. The incidence of vertebral fractures was low at 12 months (6 %) and most patients demonstrated recovery in BMD Z-scores by this time point.
Vertebral fracture (VF) incidence following glucocorticoid (GC) initiation has not been previously reported in pediatric nephrotic syndrome.
VF was assessed on radiographs (Genant method); lumbar spine bone mineral density (LS BMD) was evaluated by dual-energy X-ray absorptiometry.
Sixty-five children were followed to 12 months post-GC initiation (median age, 5.4 years; range, 2.3-17.9). Three of 54 children with radiographs (6 %; 95 % confidence interval (CI), 2-15 %) had incident VF at 1 year. The mean LS BMD Z-score was below the healthy average at baseline (mean ± standard deviation (SD), -0.5 ± 1.1; p = 0.001) and at 3 months (-0.6 ± 1.1; p < 0.001), but not at 6 months (-0.3 ± 1.3; p = 0.066) or 12 months (-0.3 ± 1.2; p = 0.066). Mixed effect modeling showed a significant increase in LS BMD Z-scores between 3 and 12 months (0.22 SD; 95 % CI, 0.08 to 0.36; p = 0.003). A subgroup (N = 16; 25 %) had LS BMD Z-scores that were ≤-1.0 at 12 months. In these children, each additional 1,000 mg/m(2) of GC received in the first 3 months was associated with a decrease in LS BMD Z-score by 0.39 at 12 months (95 % CI, -0.71 to -0.07; p = 0.017).
The incidence of VF at 1 year was low and LS BMD Z-scores improved by 12 months in the majority. Twenty-five percent of children had LS BMD Z-scores ≤-1.0 at 12 months. In these children, LS BMD Z-scores were inversely associated with early GC exposure, despite similar GC exposure compared to the rest of the cohort.
对65例肾病综合征患儿在开始使用糖皮质激素后的12个月内进行了新发椎体骨折和腰椎骨密度(BMD)评估。12个月时椎体骨折的发生率较低(6%),到这个时间点大多数患者的骨密度Z评分有所恢复。
此前尚未报道过小儿肾病综合征患者开始使用糖皮质激素(GC)后椎体骨折(VF)的发生率。
通过X线片(Genant法)评估椎体骨折;采用双能X线吸收法评估腰椎骨密度(LS BMD)。
65例患儿随访至开始使用GC后的12个月(中位年龄5.4岁;范围2.3 - 17.9岁)。54例有X线片检查的患儿中,3例(6%;95%置信区间(CI),2 - 15%)在1年时发生新发椎体骨折。基线时(均值±标准差(SD),-0.5±1.1;p = 0.001)和3个月时(-0.6±1.1;p < 0.001)平均LS BMD Z评分低于健康平均水平,但6个月时(-0.3±1.3;p = 0.066)和12个月时(-0.3±1.2;p = 0.066)并非如此。混合效应模型显示,3至12个月期间LS BMD Z评分有显著增加(0.22 SD;95% CI,0.08至0.36;p = 0.003)。一个亚组(N = 16;25%)在12个月时LS BMD Z评分≤ -1.0。在这些患儿中,前3个月每额外接受1000 mg/m²的GC,与12个月时LS BMD Z评分降低0.39相关(95% CI,-0.71至-0.07;p = 0.017)。
1年时椎体骨折的发生率较低,大多数患儿的LS BMD Z评分在12个月时有所改善。25%的患儿在12个月时LS BMD Z评分≤ -1.0。在这些患儿中,尽管与队列中的其他患儿GC暴露情况相似,但LS BMD Z评分与早期GC暴露呈负相关。